Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Medtronic
Dow
Queensland Health
Teva
US Army
Accenture
Chubb
Mallinckrodt
Covington

Generated: January 19, 2018

DrugPatentWatch Database Preview

Pfizer Ireland Company Profile

« Back to Dashboard

Summary for Pfizer Ireland
International Patents:147
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Pfizer Ireland

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Pfizer Ireland

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 ➤ Subscribe ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 ➤ Subscribe ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 ➤ Subscribe ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PFIZER IRELAND drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 3/29/2010

Non-Orange Book US Patents for Pfizer Ireland

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,380,226 Salts of an anti-migraine indole derivatives ➤ Subscribe
5,559,129 Indole derivatives ➤ Subscribe
5,559,246 Indole derivatives ➤ Subscribe
5,607,951 Indole derivatives ➤ Subscribe
5,578,612 Indole derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Pfizer Ireland Drugs

Supplementary Protection Certificates for Pfizer Ireland Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001 Austria ➤ Subscribe PRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214
C/GB01/023 United Kingdom ➤ Subscribe PRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
0592438/01 Switzerland ➤ Subscribe FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C0013 France ➤ Subscribe PRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Colorcon
Covington
Cerilliant
Citi
Harvard Business School
QuintilesIMS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot